List of Excipients in Branded Drug VARIBAR HONEY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
E-Z-EM Canada Inc	VARIBAR HONEY	barium sulfate	32909-122	ANHYDROUS CITRIC ACID
E-Z-EM Canada Inc	VARIBAR HONEY	barium sulfate	32909-122	CARBOXYMETHYLCELLULOSE SODIUM
E-Z-EM Canada Inc	VARIBAR HONEY	barium sulfate	32909-122	DIMETHICONE 1000
E-Z-EM Canada Inc	VARIBAR HONEY	barium sulfate	32909-122	DIMETHICONE 350
E-Z-EM Canada Inc	VARIBAR HONEY	barium sulfate	32909-122	GLYCERIN

VARIBAR HONEY Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

VARIBAR HONEY is a ready-to-use, honey-consistency barium sulfate oral suspension marketed by Bracco Diagnostics for videofluoroscopic modified barium swallow examinations. Its commercial value depends less on the barium sulfate active ingredient than on suspension stability, controlled rheology, palatability, dose reproducibility, and workflow integration. The product’s excipient system supports those requirements through xanthan gum, buffering agents, preservatives, sweetener, flavoring, and purified water.[1]

The principal commercial opportunity is to develop differentiated, ready-to-use contrast suspensions for dysphagia imaging, pediatric swallowing assessment, outpatient radiology, and institutional protocols. Direct substitution for VARIBAR HONEY would face regulatory and performance barriers because viscosity, sedimentation, radiopacity, microbial control, and administration characteristics are critical product attributes.

What is VARIBAR HONEY and how is it regulated?

VARIBAR HONEY is a prescription oral suspension containing barium sulfate at 40% weight/volume, equivalent to 400 mg/mL. It is administered orally during modified barium swallow examinations to evaluate the oropharyngeal swallowing mechanism in adults and pediatric patients aged 12 years and older.[1]

Attribute	Product information
Brand	VARIBAR HONEY
Active ingredient	Barium sulfate
Dosage form	Oral suspension
Strength	40% w/v, 400 mg/mL
Manufacturer	Bracco Diagnostics Inc.
FDA pathway	New Drug Application
Route	Oral
Primary use	Modified barium swallow examination
Target population	Adults and patients 12 years and older
Commercial type	Ready-to-use radiographic contrast suspension

Barium sulfate is not systemically absorbed under normal conditions. Its function is to provide radiopacity in the gastrointestinal and oropharyngeal tract. The formulation’s clinical performance therefore depends on physical properties rather than pharmacokinetic exposure.

What excipients are used in VARIBAR HONEY?

The FDA labeling identifies the product’s inactive ingredients as including xanthan gum, sodium citrate, citric acid, potassium sorbate, sodium benzoate, sucralose, flavoring components, and water.[1] Exact quantities are generally not disclosed in public labeling.

Excipient or excipient class	Likely formulation function	Commercial significance
Xanthan gum	Suspending agent and viscosity modifier	Controls flow, sedimentation, and honey-like consistency
Citric acid and sodium citrate	Buffer system and pH control	Supports product stability and taste management
Potassium sorbate	Antimicrobial preservative	Supports multidose or in-use microbial control
Sodium benzoate	Antimicrobial preservative	Provides complementary preservative activity
Sucralose	High-intensity sweetener	Improves acceptability without materially increasing solids
Flavoring agents	Honey-like palatability profile	Supports patient acceptance during swallowing studies
Purified water	Continuous phase	Determines viscosity, density distribution, and fill consistency

Why xanthan gum is strategically important

Xanthan gum is the key functional excipient in the formulation. Barium sulfate has high density and tends to settle rapidly in aqueous systems. Xanthan gum increases low-shear viscosity and provides pseudoplastic flow. The suspension can remain relatively stable at rest but become easier to pour or swallow when subjected to shear.

For a dysphagia imaging product, excessive viscosity can alter swallowing behavior and reduce clinical utility. Insufficient viscosity can produce rapid sedimentation, inconsistent concentration, and dose-to-dose variability. The target is therefore a controlled rheological profile rather than maximum thickness.

A developer seeking to compete with VARIBAR HONEY would need to characterize:

• Yield stress and apparent viscosity.
• Sedimentation rate during storage.
• Redispersibility after standing.
• Flow through the supplied container or dosing device.
• Oral coating and swallowability.
• Barium concentration uniformity at the beginning, middle, and end of container use.
• Radiographic visibility under the intended imaging protocol.

Preservative strategy

The combination of potassium sorbate and sodium benzoate provides a broad antimicrobial approach, but its performance depends on pH, preservative concentration, container closure, and in-use handling. A reformulated product would need preservative-effectiveness testing and microbial limits testing under the applicable compendial framework.

Preservative reduction could create a marketing advantage for institutions seeking simpler excipient profiles, but it could also require a single-use package, smaller fill size, improved aseptic controls, or a validated in-use period. Removing preservatives without redesigning the packaging system would create regulatory and microbiological risk.

Sweetener and flavor strategy

Sucralose and honey-oriented flavoring help distinguish VARIBAR HONEY from unflavored or less palatable barium suspensions. Patient acceptance matters because swallowing studies require cooperation and repeated administration of different consistencies.

Potential improvements include:

• Reduced sweetness for patients with taste sensitivity.
• Alternative flavor profiles for pediatric or geriatric use.
• Allergen-controlled flavor systems.
• Sugar-free and low-osmolality options.
• Flavor systems compatible with thickened-liquid dysphagia protocols.

Any flavor change could affect viscosity perception, pH, preservative performance, and patient behavior during the study. Flavor is therefore a formulation variable, not only a branding element.

What formulation patents protect VARIBAR HONEY?

Public FDA product labeling establishes the formulation and regulatory identity but does not, by itself, establish patent protection. VARIBAR HONEY is identified as an NDA product rather than a conventional small-molecule therapeutic with a clearly disclosed Orange Book patent estate.[1,2]

IP category	Publicly supportable assessment
Active-ingredient patent	Barium sulfate is an established diagnostic agent; composition-of-matter protection is not the commercial barrier
Formulation patent	Product-specific protection would need to be confirmed through current patent databases and Orange Book records
Method-of-use patent	The modified barium swallow indication may be protected through labeling, clinical know-how, or regulatory exclusivity rather than a readily identifiable composition patent
Manufacturing know-how	Likely important for particle-size control, suspension uniformity, rheology, filling, and microbial control
Trademark	VARIBAR HONEY branding is a commercial asset separate from formulation exclusivity
Trade secret exposure	Excipient concentrations, processing order, mixing energy, particle conditioning, and quality specifications may remain nonpublic

The main barrier to a generic or competing product is likely regulatory and technical equivalence rather than barium sulfate availability. A competitor must show that its product has consistent identity, strength, quality, purity, stability, and performance. For a suspension used in dynamic swallowing assessment, differences in viscosity or oral behavior could be clinically relevant.

When does VARIBAR HONEY lose exclusivity?

The FDA approved VARIBAR HONEY under NDA 208547 in 2017.[1] Any time-limited regulatory exclusivity associated with the approval would not normally remain the primary commercial barrier several years after approval. Current Orange Book records should be used to verify the live status of listed patents, exclusivity, and any approved therapeutic-equivalence pathway.[2]

No biosimilar pathway applies. VARIBAR HONEY is a nonbiologic barium sulfate suspension, so competitive entry would generally proceed through a drug application pathway rather than a biosimilar application.

Paragraph IV and generic entry risk

A Paragraph IV challenge is relevant only if an eligible patent is listed for the reference product. If no enforceable, currently listed patent covers the product, a competitor could pursue a filing strategy that does not require a Paragraph IV certification against an active listed patent.

The commercial entry scenarios are:

1. An authorized or branded alternative using a comparable ready-to-use suspension.
2. An ANDA-supported generic if the reference-product regulatory framework and FDA requirements permit the necessary equivalence showing.
3. A new NDA for a differentiated concentration, flavor, viscosity, or patient population.
4. A hospital or institutional product supplied through a contrast-media portfolio.

The most credible entrant would likely compete on price, packaging, availability, and workflow rather than on the barium sulfate molecule.

What manufacturing and IP barriers affect competing products?

Manufacturing know-how can be more valuable than the disclosed excipient list. Relevant process controls include:

• Barium sulfate particle-size distribution.
• Deagglomeration and wetting.
• Order of excipient addition.
• Hydration time for xanthan gum.
• Mixing shear and batch hold time.
• Air entrapment control.
• Homogeneity during filling.
• Container orientation and sedimentation behavior.
• Preservative distribution.
• Stability after transport and temperature cycling.

A formulation that matches the labeled ingredients but fails to reproduce the product’s flow and redispersibility may not be clinically or commercially interchangeable.

Container design is another barrier. Ready-to-use packaging must limit contamination, permit efficient administration, and allow users to identify adequate resuspension. Single-dose containers could reduce preservative requirements but increase packaging and logistics costs. Multidose bottles may improve cost efficiency but create greater in-use microbial and handling requirements.

What commercial opportunities exist around VARIBAR HONEY excipients?

Ready-to-use dysphagia formulations

The strongest opportunity is a portfolio of oral barium suspensions with controlled consistencies aligned with clinical swallowing protocols. Products could target thin-liquid, nectar-like, honey-like, and pudding-like administration profiles. Consistency should be defined through validated rheological measurements rather than marketing terminology alone.

Pediatric and geriatric products

Patients with dysphagia often have limited tolerance for unpleasant taste, excessive sweetness, or large administration volumes. Smaller packages, improved flavor, and lower sensory burden could support adoption in pediatric hospitals, long-term-care facilities, and outpatient imaging centers.

Excipient-reduced products

A product with fewer preservatives, a simplified flavor system, or alternative sweetening could appeal to institutions managing excipient sensitivities. The commercial case depends on whether the change improves clinical acceptance enough to offset higher packaging or manufacturing costs.

Institutional supply and workflow products

Hospitals may value:

• Unit-dose packaging.
• Barcode-ready labeling.
• Pre-measured study kits.
• Protocol-specific concentration and viscosity.
• Reduced preparation time.
• Consistent product availability.
• Integration with radiology inventory systems.

A supplier could also offer bundled products covering the full modified barium swallow workflow, including multiple consistencies and standardized administration volumes.

Contract manufacturing and private-label supply

Because barium sulfate is widely available, private-label supply could be viable if the manufacturer can reproduce suspension performance and meet FDA quality requirements. The principal commercial assets would be formulation know-how, validated manufacturing, regulatory documentation, and reliable supply rather than exclusive access to the active ingredient.

How does VARIBAR HONEY compare with conventional barium suspensions?

Factor	VARIBAR HONEY	Conventional hospital-prepared barium
Preparation	Ready to use	May require preparation or dilution
Viscosity	Designed for honey-like consistency	Can vary by product and preparation
Dose consistency	Factory-controlled	Operator-dependent
Palatability	Sweetened and flavored	Often less differentiated
Workflow	Supports standardized protocol	More preparation steps
Cost structure	Higher unit product cost possible	Lower material cost but higher labor variability
Competitive weakness	Branded product premium	Flexibility and price
Competitive opportunity	Standardization and convenience	Customization and institutional economics

What is the FDA and Orange Book status of VARIBAR HONEY?

VARIBAR HONEY is an FDA-approved prescription diagnostic product under NDA 208547.[1] The Orange Book is the relevant source for current patent listings, exclusivity status, and therapeutic-equivalence information.[2] Because product-specific patent status can change through listing, delisting, expiration, or regulatory updates, commercial diligence should treat the current Orange Book record as controlling.

No biosimilar risk applies. Generic risk is more relevant, but entry would require a credible demonstration of pharmaceutical quality and comparable performance for a complex suspension dosage form.

What patent litigation and settlements affect VARIBAR HONEY?

No widely reported patent litigation or settlement is identified in the FDA product materials cited for VARIBAR HONEY. The absence of a prominent public dispute does not eliminate the possibility of private patent rights, contractual restrictions, or later-filed formulation claims. The more material competitive risks appear to be formulation replication, regulatory approval, manufacturing scale, and institutional contracting.

What revenue exposure does VARIBAR HONEY create?

Bracco does not publicly disclose product-level VARIBAR HONEY revenue in the cited regulatory materials. Exposure should therefore be modeled using institutional volume rather than reported brand sales.

Key commercial variables include:

• Number of modified barium swallow studies.
• Adoption rate in hospitals and outpatient imaging centers.
• Average units consumed per study.
• Product mix across Varibar consistencies.
• Contract pricing and group purchasing arrangements.
• Replacement rate for hospital-prepared alternatives.
• Supply reliability and shortage exposure.
• Reimbursement treatment for the diagnostic procedure.

The product is most commercially defensible where standardized viscosity and reduced preparation labor have measurable value. Price-only competition would weaken the brand unless supported by better availability, packaging, or clinical workflow evidence.

Key Takeaways

• VARIBAR HONEY is a 40% w/v ready-to-use barium sulfate oral suspension for modified barium swallow examinations.
• Xanthan gum is the central excipient for controlling suspension stability and honey-like rheology.
• Citrate buffering, potassium sorbate, sodium benzoate, sucralose, flavoring, and water support pH control, microbial protection, and patient acceptance.
• The principal competitive barrier is formulation and manufacturing performance, not the barium sulfate molecule.
• No biosimilar pathway applies; generic or branded alternative entry is the relevant risk.
• Product-specific patent protection should be verified through current Orange Book and patent records rather than inferred from FDA labeling.
• Commercial opportunities include pediatric products, excipient-reduced formulations, unit-dose packaging, protocol-specific consistencies, and private-label supply.
• Bracco does not disclose product-level revenue in the cited materials, so market sizing requires procedure-volume and institutional-adoption assumptions.

FAQs

Can VARIBAR HONEY be reformulated without xanthan gum?

Yes, but replacing xanthan gum would require redevelopment of suspension stability, viscosity, redispersibility, dosing uniformity, and clinical handling characteristics. A substitute polymer could materially change swallowing behavior.

Is VARIBAR HONEY a conventional pharmaceutical drug?

It is an FDA-approved prescription diagnostic drug product. Its clinical value comes from radiopacity and physical administration characteristics rather than systemic pharmacologic activity.

Could a competitor launch a sugar-free VARIBAR HONEY alternative?

A sugar-free product could be developed because the labeled formulation uses sucralose rather than conventional nutritive sugar. The competitor would still need to match taste, viscosity, stability, preservative performance, and regulatory quality requirements.

What is the most defensible commercial feature of VARIBAR HONEY?

The strongest defensible feature is the integrated product profile: standardized honey-like consistency, ready-to-use presentation, palatability, suspension uniformity, and compatibility with dysphagia imaging workflows.

Does VARIBAR HONEY have biosimilar competition?

No. Barium sulfate suspensions are nonbiologic drug products. Competition would arise through generic, branded-generic, alternative NDA, or private-label pathways.

References

1. U.S. Food and Drug Administration. (2017). VARIBAR HONEY (barium sulfate) oral suspension, prescribing information. Bracco Diagnostics Inc. DailyMed.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.